Rate control drugs differ in the prevention of progression of atrial fibrillation

T. Koldenhof; P.E.P.J. Wijtvliet; N.A.H.A. Pluymaekers; M. Rienstra; R.J. Folkeringa; P. Bronzwaer; A. Elvan; J. Elders; R. Tukkie; J.G.L.M. Luermans; S.M.J. van Kuijk; J.G.P. Tijssen; I.C. van Gelder; H.J.G.M. Crijns; R.G. Tieleman

doi:10.1093/europace/euab191

Rate control drugs differ in the prevention of progression of atrial fibrillation

T. Koldenhof^*, P.E.P.J. Wijtvliet, N.A.H.A. Pluymaekers, M. Rienstra, R.J. Folkeringa, P. Bronzwaer, A. Elvan, J. Elders, R. Tukkie, J.G.L.M. Luermans, S.M.J. van Kuijk, J.G.P. Tijssen, I.C. van Gelder, H.J.G.M. Crijns, R.G. Tieleman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	384-389
Number of pages	6
Journal	EP Europace
Volume	24
Issue number	3
Early online date	20 Aug 2021
DOIs	https://doi.org/10.1093/europace/euab191
Publication status	Published - 2 Mar 2022

Keywords

Atrial fibrillation
Atrial fibrillation progression
Rate control
Rhythm control
RACE 4 study
VERAPAMIL
TACHYCARDIA
ARRHYTHMOGENESIS
CARDIOVERSION
DIGOXIN
RISK

Access to Document

10.1093/europace/euab191Licence: CC BY-NC

Cite this

Koldenhof, T., Wijtvliet, P. E. P. J., Pluymaekers, N. A. H. A., Rienstra, M., Folkeringa, R. J., Bronzwaer, P., Elvan, A., Elders, J., Tukkie, R., Luermans, J. G. L. M., van Kuijk, S. M. J., Tijssen, J. G. P., van Gelder, I. C., Crijns, H. J. G. M., & Tieleman, R. G. (2022). Rate control drugs differ in the prevention of progression of atrial fibrillation. EP Europace, 24(3), 384-389. https://doi.org/10.1093/europace/euab191

Koldenhof, T. ; Wijtvliet, P.E.P.J. ; Pluymaekers, N.A.H.A. ; Rienstra, M. ; Folkeringa, R.J. ; Bronzwaer, P. ; Elvan, A. ; Elders, J. ; Tukkie, R. ; Luermans, J.G.L.M. ; van Kuijk, S.M.J. ; Tijssen, J.G.P. ; van Gelder, I.C. ; Crijns, H.J.G.M. ; Tieleman, R.G. / Rate control drugs differ in the prevention of progression of atrial fibrillation. In: EP Europace. 2022 ; Vol. 24, No. 3. pp. 384-389.

@article{24de402d3841476d8a10b6f7d70deed3,

title = "Rate control drugs differ in the prevention of progression of atrial fibrillation",

keywords = "Atrial fibrillation, Atrial fibrillation progression, Rate control, Rhythm control, RACE 4 study, VERAPAMIL, TACHYCARDIA, ARRHYTHMOGENESIS, CARDIOVERSION, DIGOXIN, RISK",

author = "T. Koldenhof and P.E.P.J. Wijtvliet and N.A.H.A. Pluymaekers and M. Rienstra and R.J. Folkeringa and P. Bronzwaer and A. Elvan and J. Elders and R. Tukkie and J.G.L.M. Luermans and {van Kuijk}, S.M.J. and J.G.P. Tijssen and {van Gelder}, I.C. and H.J.G.M. Crijns and R.G. Tieleman",

year = "2022",

month = mar,

day = "2",

doi = "10.1093/europace/euab191",

language = "English",

volume = "24",

pages = "384--389",

journal = "EP Europace",

issn = "1099-5129",

publisher = "Oxford University Press",

number = "3",

}

Koldenhof, T, Wijtvliet, PEPJ, Pluymaekers, NAHA, Rienstra, M, Folkeringa, RJ, Bronzwaer, P, Elvan, A, Elders, J, Tukkie, R, Luermans, JGLM , van Kuijk, SMJ, Tijssen, JGP, van Gelder, IC, Crijns, HJGM & Tieleman, RG 2022, 'Rate control drugs differ in the prevention of progression of atrial fibrillation', EP Europace, vol. 24, no. 3, pp. 384-389. https://doi.org/10.1093/europace/euab191

Rate control drugs differ in the prevention of progression of atrial fibrillation. / Koldenhof, T.; Wijtvliet, P.E.P.J.; Pluymaekers, N.A.H.A.; Rienstra, M.; Folkeringa, R.J.; Bronzwaer, P.; Elvan, A.; Elders, J.; Tukkie, R.; Luermans, J.G.L.M.; van Kuijk, S.M.J.; Tijssen, J.G.P.; van Gelder, I.C.; Crijns, H.J.G.M.; Tieleman, R.G.

In: EP Europace, Vol. 24, No. 3, 02.03.2022, p. 384-389.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rate control drugs differ in the prevention of progression of atrial fibrillation

AU - Koldenhof, T.

AU - Wijtvliet, P.E.P.J.

AU - Pluymaekers, N.A.H.A.

AU - Rienstra, M.

AU - Folkeringa, R.J.

AU - Bronzwaer, P.

AU - Elvan, A.

AU - Elders, J.

AU - Tukkie, R.

AU - Luermans, J.G.L.M.

AU - van Kuijk, S.M.J.

AU - Tijssen, J.G.P.

AU - van Gelder, I.C.

AU - Crijns, H.J.G.M.

AU - Tieleman, R.G.

PY - 2022/3/2

Y1 - 2022/3/2

KW - Atrial fibrillation

KW - Atrial fibrillation progression

KW - Rate control

KW - Rhythm control

KW - RACE 4 study

KW - VERAPAMIL

KW - TACHYCARDIA

KW - ARRHYTHMOGENESIS

KW - CARDIOVERSION

KW - DIGOXIN

KW - RISK

U2 - 10.1093/europace/euab191

DO - 10.1093/europace/euab191

M3 - Article

C2 - 34414430

VL - 24

SP - 384

EP - 389

JO - EP Europace

JF - EP Europace

SN - 1099-5129

IS - 3

ER -